A. Radinoff

发表

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

D. Faller, L. Adès, J. Liesveld, 2021, Leukemia.

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial

C. Klade, H. Gisslinger, N. Tzvetkov, 2019, British journal of haematology.

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

K. Götze, P. Fenaux, A. Symeonidis, 2018, Leukemia.

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

M. Dimopoulos, S. Jagannath, P. Richardson, 2020, The Lancet.

Nevus Blue as a Sporadic Finding in a Patient with a Blue Toe?

U. Wollina, G. Tchernev, I. Temelkova, 2018, Open Access Macedonian Journal of Medical Sciences.

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Angela G. Fleischman, A. Salar, S. Verstovsek, 2023, The Lancet.

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

F. Mannelli, A. Vannucchi, F. Passamonti, 2021, Leukemia.

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

S. Jagannath, P. Richardson, R. Benjamin, 2021, Blood.

A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.

M. Dimopoulos, M. Matsumoto, T. Masszi, 2023, Journal of Clinical Oncology.

An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

T. Robak, N. Tzvetkov, G. Iosava, 2020 .